Integral Diagnostics

Integral Diagnostics Revenue

The The revenue of Integral Diagnostics (IDX.AX) as of Nov 5, 2026 is 788.62 M AUD. In the previous year, The revenue was 627.22 M AUD — a change of 25.73% (higher).

Revenue

788.62 MAUD

YoY

25.73%

Last updated:

In 2026, Integral Diagnostics's sales reached 788.62 M AUD, a 25.73% difference from the 627.22 M AUD sales recorded in the previous year.

Over the last 14 years Integral Diagnostics grew revenue by 48.9% annually, reaching 788.62 M AUD.

The Integral Diagnostics Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2024
469.70 M AUD
Jan 1, 2025
627.22 M AUD
Jan 1, 2026
788.62 M AUD
Jan 1, 2027 (e)
838.77 M AUD
Jan 1, 2028 (e)
885.79 M AUD
Jan 1, 2029 (e)
935.55 M AUD
Jan 1, 2030 (e)
1.00 B AUD
Jan 1, 2031 (e)
1.06 B AUD
The Integral Diagnostics Revenue history
YEARRevenueYoY
est1.06 BAUD+5.14%
est1.00 BAUD+7.26%
est935.55 MAUD+5.62%
est885.79 MAUD+5.61%
est838.77 MAUD+6.36%
788.62 MAUD+25.73%
627.22 MAUD+33.54%
469.70 MAUD+6.73%
440.10 MAUD+22.68%
358.74 MAUD+2.85%
348.81 MAUD+27.26%
274.08 MAUD+17.94%
232.39 MAUD+22.70%
189.40 MAUD+5.38%
179.73 MAUD+7.13%
167.77 MAUD+10.95%
151.21 MAUD+3,570.22%
4.12 MAUD+27.55%
3.23 MAUD+8.03%
2.99 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integral Diagnostics Revenue

Integral Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
469.70 M AUD
42.17 M AUD
-60.70 M AUD
Jan 1, 2025
627.22 M AUD
57.53 M AUD
4.67 M AUD
Jan 1, 2026
788.62 M AUD
67.65 M AUD
21.93 M AUD
Jan 1, 2027 (e)
838.77 M AUD
99.05 M AUD
41.04 M AUD
Jan 1, 2028 (e)
885.79 M AUD
110.52 M AUD
49.03 M AUD
Jan 1, 2029 (e)
935.55 M AUD
119.73 M AUD
54.10 M AUD
Jan 1, 2030 (e)
1.00 B AUD
136.88 M AUD
63.32 M AUD
Jan 1, 2031 (e)
1.06 B AUD
0.00 AUD
80.74 M AUD

Integral Diagnostics Margins

Integral Diagnostics stock margins

The Integral Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integral Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integral Diagnostics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
95.12 %
8.98 %
-12.92 %
Jan 1, 2025
95.52 %
9.17 %
0.75 %
Jan 1, 2026
21.37 %
8.58 %
2.78 %
Jan 1, 2027 (e)
21.37 %
11.81 %
4.89 %
Jan 1, 2028 (e)
21.37 %
12.48 %
5.54 %
Jan 1, 2029 (e)
21.37 %
12.80 %
5.78 %
Jan 1, 2030 (e)
21.37 %
13.64 %
6.31 %
Jan 1, 2031 (e)
21.37 %
0.00 %
7.65 %

Integral Diagnostics Stock analysis

What does Integral Diagnostics do? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Integral Diagnostics's Sales Figures

The sales figures of Integral Diagnostics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Integral Diagnostics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Integral Diagnostics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Integral Diagnostics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Integral Diagnostics stock

The revenue of Integral Diagnostics is 788.62 M AUD in 2026.

The revenue of Integral Diagnostics changed from 627.22 M AUD to 788.62 M AUD, representing a 25.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Integral Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Integral Diagnostics historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Integral Diagnostics

All Key Metrics — Integral Diagnostics